Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Abstract Background Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor response and prognosis. More...

Full description

Bibliographic Details
Main Authors: John F. Seymour, Hartmut Döhner, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Jose Falantes, Richard M. Stone, Mark D. Minden, Jerry Weaver, Steve Songer, C. L. Beach, Hervé Dombret
Format: Article
Language:English
Published: BMC 2017-12-01
Series:BMC Cancer
Subjects:
Azacitidine
Low-dose cytarabine
Acute myeloid leukaemia
AML
Myelodysplasia-related changes
AML-MRC
Online Access:http://link.springer.com/article/10.1186/s12885-017-3803-6

Internet

http://link.springer.com/article/10.1186/s12885-017-3803-6

Similar Items